The companies that have obtained financing in this round of concentration cover seven high prosperity sub sectors, including brain computer interfaces, AI for Science, iPSC cell therapy, extracellular vesicle technology, nuclear drug research and development, cross-border medical device services, exoskeleton robots, etc., comprehensively covering core industries such as high-end medical devices, cell therapy, AI medicine, and cross-border medical services. The financing scale covers millions to billions of yuan, covering the entire financing cycle including angel round, Pre-A round, A round, B round, etc. Such enterprises are deeply involved in the research and development of core technologies, relying on their independent innovation capabilities to break through industry bottlenecks in core technologies and promote the process of domestic substitution in the high-end medical field.

---

1、 Zhongke Borui has received tens of millions of yuan in Series B financing to promote the clinical transformation of the entire brain computer interface industry chain

On March 10th, Zhongke Borui, a high-end medical device enterprise incubated by the Institute of Automation of the Chinese Academy of Sciences, announced the completion of tens of millions of yuan in Series B financing, with investment from Sanze Venture Capital and long-term exclusive financial advisor from Kaicheng Capital. The funds will be used for the research and development of core technologies for brain computer interfaces, product iteration, and industrialization, supporting the country’s future industrial strategic layout during the 15th Five Year Plan period.

Zhongke Borui is a national high-tech enterprise and a “specialized, refined, and innovative” enterprise in Beijing. It has built a “brain computer interface+artificial intelligence” technology platform and formed a full industry chain layout from research and development to manufacturing and clinical applications. The company independently develops the world’s first non-invasive whole brain multi-channel cerebral oxygen monitor, optoelectronic synchronous brain functional imaging device and other high-end products. The core technology is independently controllable, breaking the monopoly of foreign technology. It has obtained 2 national innovative devices, 8 NMPA registration certificates and CE certification, and its products cover more than 600 hospitals across the country.

The company is led by Professor Jiang Tianzai, a member of the European Academy of Sciences, as the chief scientist, and his research achievements have won the first prize of the Beijing Medical Science and Technology Award. After this round of financing, Zhongke Borui will continue to strengthen its intellectual property layout, expand clinical scenarios such as neurosurgery, critical care, and rehabilitation, build a “diagnosis monitoring treatment rehabilitation” full cycle brain health medical ecosystem, and accelerate the independent, controllable, and globalized landing of China’s brain computer interface industry.

---

2、 MetaNovas has completed consecutive A+and A++rounds of financing, with Agentic AI empowering molecular research and industrialization

On March 9th, MetaNovas, the world’s first technology company to commercialize AI designed molecular new materials, announced that it has completed two consecutive rounds of financing, A+and A++. This round of financing is jointly invested by industry leaders such as Kangaroo Mama Group and Yayan Group, as well as financial institutions such as Fuhua Capital and Hillhouse Capital, with Kaicheng Capital serving as the long-term exclusive financial advisor. Previously, the company had completed multiple rounds of financing, and the capital intensive injection demonstrated its high recognition of its technological landing capabilities and commercial value.

MetaNovas is deeply involved in the AI for Science field, focusing on the pain points of “heavy generation, light landing” in molecular research and development, and creating the core system MetAmigo for Agentic AI’s independent research and development system. This system has interdisciplinary reasoning and multi-objective decision-making capabilities, and can pre position process and regulatory constraints, optimizing the research and development process through human-machine collaborative evolution. Based on core technologies such as the MUniGen molecular language model with 28 billion parameters, its molecular structure efficiency exceeds 95%, and the consistency between performance prediction and wet experimental verification exceeds 92%.

At present, the company’s AI design team has landed on top brands of cosmetics and medical devices in China and the United States, completed global compliance filing, and covered more than 600 hospitals. After this round of financing, MetaNovas will deepen the research and development of Agentic AI technology, focusing on fields such as medical devices and biomedicine, promoting the transformation of AI for Science from a research paradigm to an industrial reality, and reshaping the molecular research and development industry landscape.

---

3、 Aikai Biotechnology has secured over 100 million yuan in A3 round financing, accelerating the industrialization process of iPSC technology empowered by AI

On March 9th, Aikai Biotechnology, an innovative biotech company focused on the transformation of iPSC technology, completed its A3 round of financing exceeding 100 million yuan. This round of financing was jointly led by Wojie Capital and Zhiyi Investment, with Lianxin Capital continuing to follow suit. The funds raised this time will be mainly used to promote the clinical implementation of multiple AI driven research and development systems for allogeneic universal iPSC derived cell new drugs, while also strengthening the upgrading and improvement of the company’s two core technology platforms for iPSC cell therapy and iPSC organoids, helping its AI driven cell therapy and drug screening development model enter a critical validation stage.

As a pioneer in the field of iPSC technology, Aikai Biotechnology has established an independent AI driven predictive model development system, deeply integrating artificial intelligence into the entire process of cell reprogramming, directed differentiation, and quality control. Relying on the new generation of reprogramming and precise gene editing technology, it has created a low immunogenicity universal cell chassis, focusing on the treatment of neurological diseases such as Parkinson’s and epilepsy. Relevant products have made phased clinical progress, and the AI+iPSC organoid platform built simultaneously has also achieved core functions of disease modeling and drug development verification.

At present, Aikai Biotechnology has established a research and development, production, and clinical translation industry chain covering China and Australia, and has established deep cooperation with top international clinical institutions. The implementation of this round of financing will further strengthen its core competitiveness in the integration of AI and iPSC technology, accelerate the global clinical promotion of core products, and promote the large-scale industrial application of iPSC technology in the field of regenerative medicine.

---

4、 Zhongke Yiwei has completed a 10 million yuan Pre-A round of financing, achieving breakthroughs in both extracellular vesicle core nanotechnology and standardization construction

On March 6th, Suzhou Zhongke Yiwei Technology Development Co., Ltd. completed a 10 million yuan Pre-A round of financing, with exclusive strategic investment from Changchun Changxing Fund. The funds will be mainly used for the research and industrialization of extracellular vesicle anti-aging system products, consolidating the batch and standardized nanotechnology system for extracellular vesicle preparation.

Zhongke Yiwei’s core technology originates from the transformation of achievements by the National Center for Nanoscience and Technology, and builds iMAF ™ Accurate capture and detection of extracellular vesicles SuperEV ™ Two core technology platforms for automated macro scale preparation, forming a fully independent intellectual property system. iMAF ™ By relying on functionalized microspheres, exosomes can be captured without overspeed centrifugation, breaking the limit of flow cytometry detection and achieving precise quantification of over 10 target pg/mL. The entire process takes less than 2 hours and is suitable for the diagnosis of aging related diseases such as tumors and neurodegenerative diseases. SuperEV ™ Through fully automated 3D cell culture, 10-50L scale purification, and optimized freeze-drying process, we have achieved standardized preparation of extracellular vesicles on a large scale, overcome the challenge of encapsulating functional molecules, and developed core medical beauty materials such as EVPlus.

 

The founder of the company led the development of national standards for extracellular vesicles and pre approved ISO international standards, filling the gap in industry standards. This round of financing will promote the construction of its GMP plant and the research and development of extracellular vesicle drugs and drug device combinations, driven by technological innovation and standard construction, accelerating the industrialization of extracellular vesicles in the fields of diagnosis, treatment, and overall health.

---

5、 Sai Nuclear Biotechnology has completed tens of millions of angel+round financing, breaking through the bottleneck of alpha nuclear drug research and development with original nuclide coupling technology

On March 6th, Hangzhou Saihe Biotechnology Co., Ltd. completed tens of millions of angel+round financing, led by Fir Creek Capital and followed by Longtai Investment. The funds will be directed towards promoting core pipeline clinical trials, developing innovative technologies for nuclear drugs, and building professional talent teams, focusing on the clinical translation and application of Alpha nuclear targeted therapy technology.

Sai Nuclear Biotechnology is deeply involved in the research and development of radiopharmaceuticals, with a core layout in the field of alpha particle radiotherapy technology. We have independently developed the world’s first nuclide coupling platform technology, breaking through the core bottlenecks of traditional nuclear drug targeted delivery and target binding stability, and achieving precise delivery of radioactive isotopes to tumor tissues. It has the characteristics of strong killing, high specificity, and integrated diagnosis and treatment, providing a new treatment plan for various types of cancer. This technology is regarded as a new generation of core technology path in the field of tumor treatment after immunotherapy and cell therapy.

The core team of the company is composed of experts in the fields of radiochemistry and biomedical engineering from top universities such as Duke University and Washington University in St. Louis, and has established a fully independent intellectual property system in the field of nuclear medicine. This round of financing will further promote the industrialization of its original technology, accelerate the tackling of key challenges in the clinical application of nuclear drugs, and help Alpha nuclear drugs achieve technological breakthroughs and clinical popularization in the field of precision cancer treatment.

---

6、 Mglobal completes millions of yuan angel round financing, empowering China Machinery ASEAN to go global with its technological service system

On March 5th, Mglobal, which focuses on cross-border trade of medical devices, completed a multi million yuan angel round financing, exclusively invested by Kailos Capital. The funds will be used to build a dual engine resource network of “Chinese industry end+ASEAN market end”, upgrade cross-border digital service system, and expand global channels, using technological service capabilities to solve industry pain points such as compliance and resource docking for China’s medical device going global.

 

Mglobal has established a technology service architecture that integrates the Hong Kong headquarters, Kuala Lumpur, and Changsha offices, relying on supply chain integration technology and local compliance service systems to achieve precise alignment between China’s medical equipment production capacity and ASEAN market demand. On the industrial side, we integrate high-end manufacturing resources from over 10 medical listed companies and dozens of high-quality enterprises. On the market side, we use Malaysia as a technology hub to build a compliant channel technology system covering ASEAN. We deeply connect with local medical terminals and regulatory agencies to achieve technical process control for product compliance and implementation.

 

The company focuses on clinical essential fields such as IVD and hemodialysis, creating a technical product matrix of high, medium, and low value medical consumables, while constructing a diversified business technology model of “cross-border trade+regional agency+equity transfer”. This round of financing will further strengthen its digital supply chain services and local compliance technology capabilities, create a technological cross-border service benchmark for China Medical Equipment’s overseas expansion, and promote the globalization and inclusiveness of China’s medical technology resources.

---

7、 Chengtian Technology has completed a billion yuan B+round of financing, driven by technological innovation to upgrade the human-machine fusion of exoskeleton robots

On March 5th, Hangzhou Chengtian Technology completed a billion yuan B+round of financing, led by Agricultural Bank of China Capital, with joint investment from Huichuan Industrial Investment and Hangzhou Capital, and Haoyue Capital serving as the long-term exclusive financial advisor. The funds will be invested in expanding the consumer grade exoskeleton market, developing embodied intelligent exoskeleton technology, and registering new brain computer interface products to accelerate the large-scale implementation of technology in the fields of consumption and rehabilitation for the elderly.

Chengtian Technology has independently developed the core algorithm and components of exoskeleton robots, and built a full industry chain technology platform that integrates human-computer interaction, intelligent sensing, and data analysis. It has accumulated more than 500 intellectual property rights and its core technology is independently controllable. It integrates AI large models and high-precision sensing technology to achieve human signal capture at a rate of 100 times per second, with a response delay of less than 0.05 seconds and a recognition accuracy of 98.7%. It can dynamically adapt to user assistance needs; At the same time, we have broken through modular design technology and launched the world’s first modular wearable assistive exoskeleton, reserving VR and AI expansion interfaces to achieve flexible hardware and service upgrades.

The company relies on medical grade technology accumulation to carry out research on the collaborative treatment of neural interfaces and exoskeletons, completing the technological transformation from medical rehabilitation to consumer level applications, and forming a full scenario product matrix covering medical, health, and industrial fields. This round of financing will further strengthen the research and development of cutting-edge technologies such as embodied intelligence and brain computer interfaces, and promote the evolution of exoskeleton robots towards intelligent and ubiquitous human-machine fusion carriers.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.